News | April 06, 2022
ENTOD Pharma bullish on Macushield sales
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
BVX-0922 to target colorectal cancer under investigator-sponsored IND
Subscribe To Our Newsletter & Stay Updated
